menu
    • menu
    [{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Urinastatin","moa":"enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bharat Serums & Vaccines ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Serums & Vaccines ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Serums & Vaccines ltd \/ Undisclosed"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bharat Serums & Vaccines ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bharat Serums & Vaccines ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Serums & Vaccines ltd \/ Undisclosed"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Carboprost Tromethamine","moa":"Prostanoid FP receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bharat Serums & Vaccines ltd","amount2":1.6399999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":1.6399999999999999,"dosageForm":"Injection","sponsorNew":"Bharat Serums & Vaccines ltd \/ Mankind Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Serums & Vaccines ltd \/ Mankind Pharma"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Carboprost Tromethamine","moa":"Prostanoid FP receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bharat Serums & Vaccines ltd","amount2":1.6399999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":1.6399999999999999,"dosageForm":"Injection","sponsorNew":"Bharat Serums & Vaccines ltd \/ Mankind Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Serums & Vaccines ltd \/ Mankind Pharma"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Epicord","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Bharat Serums & Vaccines ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Serums & Vaccines ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bharat Serums & Vaccines ltd \/ Undisclosed"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Jagdale Industries","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Isoxsuprine Hydrochloride","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bharat Serums & Vaccines ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bharat Serums & Vaccines ltd \/ Bharat Serums & Vaccines ltd","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Serums & Vaccines ltd \/ Bharat Serums & Vaccines ltd"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Recombinant-Human Follicle Stimulating Hormone","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bharat Serums & Vaccines ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Serums & Vaccines ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Serums & Vaccines ltd \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Bharat Serums & Vaccines ltd

    Menu

    Bharat Serums & Vaccines ltd

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bharat Serums & Vaccines ltd

                            India arrow
                            AllPack Indonesia
                            Not Confirmed

                            Bharat Serums & Vaccines ltd

                            India arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carboprost Tromethamine

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Mankind Pharma

                            Deal Size : $1,637.3 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Mankind Pharma Completes Landmark Acquisition of BSV

                            Details : Through the acquisition of BSV, Mankind will enhance its pipelines including Endoprost (carboprost tromethamine), which is indicated for the treatment of post partum haemorrhage.

                            Product Name : Endoprost

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 23, 2024

                            Lead Product(s) : Carboprost Tromethamine

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Mankind Pharma

                            Deal Size : $1,637.3 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bharat Serums & Vaccines ltd

                            India arrow
                            AllPack Indonesia
                            Not Confirmed

                            Bharat Serums & Vaccines ltd

                            India arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carboprost Tromethamine

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Mankind Pharma

                            Deal Size : $1,640.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            India's Mankind Pharma to Buy Bharat Serums in a $1.6 Billion Deal

                            Details : Through the acquisition of BSV, Mankind will enhance its pipelines including Endoprost (Carboprost Tromethamine), which is indicated for the treatment of post partum haemorrhage.

                            Product Name : Endoprost

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 26, 2024

                            Lead Product(s) : Carboprost Tromethamine

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Mankind Pharma

                            Deal Size : $1,640.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bharat Serums & Vaccines ltd

                            India arrow
                            AllPack Indonesia
                            Not Confirmed

                            Bharat Serums & Vaccines ltd

                            India arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isoxsuprine Hydrochloride

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Recipient : Jagdale Industries

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Bharat Serums and Vaccines Acquires Key Women Health Brand Tidilan from Jagdale Industries

                            Details : Tidilan is currently available in tablet and injectable dosage forms. BSV has some of the leading women’s health brands such as Rhoclone, Hucog, Hucog 5000 HP, AntiD among others.

                            Product Name : Tidilan

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 05, 2022

                            Lead Product(s) : Isoxsuprine Hydrochloride

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Recipient : Jagdale Industries

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bharat Serums & Vaccines ltd

                            India arrow
                            AllPack Indonesia
                            Not Confirmed

                            Bharat Serums & Vaccines ltd

                            India arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant-Human Follicle Stimulating Hormone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Recombinant Follicle-stimulating Hormone in Treatment for Infertility

                            Details : Recombinant-Human Follicle Stimulating Hormone is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Infertility, Female.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            March 04, 2022

                            Lead Product(s) : Recombinant-Human Follicle Stimulating Hormone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bharat Serums & Vaccines ltd

                            India arrow
                            AllPack Indonesia
                            Not Confirmed

                            Bharat Serums & Vaccines ltd

                            India arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leuprolide Acetate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

                            Details : Leuprolide Acetate is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            June 04, 2021

                            Lead Product(s) : Leuprolide Acetate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bharat Serums & Vaccines ltd

                            India arrow
                            AllPack Indonesia
                            Not Confirmed

                            Bharat Serums & Vaccines ltd

                            India arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epicord

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection

                            Details : Epicord is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 08, 2021

                            Lead Product(s) : Epicord

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Bharat Serums & Vaccines ltd

                            India arrow
                            AllPack Indonesia
                            Not Confirmed

                            Bharat Serums & Vaccines ltd

                            India arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Urinastatin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bharat Serums to assess sepsis drug Ulinastatin for Covid-19

                            Details : The trial will involve approximately 120 patients who have mild to moderate symptoms of acute ARDS. The drug is expected to improve recovery time and also mitigate mortality rates.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 09, 2020

                            Lead Product(s) : Urinastatin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth